Changes in Hong Kong stocks | Baoji Pharmaceutical-B (02659) rose more than 9% in early trading, clinical research and commercialization of core products gradually progressed

The Zhitong Finance App learned that Baoji Pharmaceutical-B (02659) rose more than 9% in early trading. As of press release, it rose 6.78% to HK$14.8, with a turnover of HK$11.087 million.

According to news, in the first half of the year, Baoji Pharmaceutical ushered in a good harvest period of commercialization, and the company officially entered the fast track of commercialization and international two-wheel drive. According to Guoxin Securities, KJ017 was approved for listing in China in March 2026 to aid subcutaneous infusion, and published two phase 3 clinical study data in the “European Journal of Pharmacy and Biopharmaceutics”; the company continued to expand cooperation. As of the 2026 interim report, more than 60 partners had used KJ017 for product development, and the project covered various stages from early research to clinical development.

In addition, the domestic marketing application for KJ103 for desensitization treatment before kidney transplantation was submitted and accepted by the Drug Administration in May 2026; a phase 3 clinical study on desensitization treatment for highly sensitive kidney transplant patients reached the main end in March 2026, with rapid desensitization effects, high success rate, and good safety; clinical phase 2 study data on anti-GBM disease was presented at the European Kidney Association Conference in June 2026, showing initial clinical value. Since its launch, SJ02 has completed online procurement platform listing and market entry in 29 provinces in China under the marketing promotion of partners, covering more than 70 medical institutions.